Baraclude Bests Hepsera On Viral Load Reduction In HBV Patients – Bristol Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Study shows that 58 percent of Baraclude-treated patients achieved undetectable viral load at 48 weeks versus 19 percent taking adefovir.
You may also be interested in...
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
Gilead Plans Viread Filing For Hepatitis B By Year End
Phase III data shows significant improvement in viral load in HBV patients treated with Viread versus Hepsera.